Fidson, GB Pharma partner to provide high quality, cheap medicines

NIGERIA pharmaceutical company, Fidson Healthcare Plc, has recently made a giant leap toward addressing Nigeria’s pharmaceutical needs by entering into an agreement with the American company, GB Pharma Holdings.

According to a press statement by Fidson, their business agreement is expected to provide Fidson with the guidance it needs to establish its foothold within the United States (U.S.) and to develop strategic relationships with other business entities.

The statement noted: “Of all these entities, US Pharmacopeia (USP) is the most critical. It will insure Fidson’s growth by helping it sustain U.S. and international standards. Founded in 1820, this scientific nonprofit organization will share with Fidson its expertise by overseeing the identity, strength, quality and purity of medicines, food ingredients and dietary supplements that Fidson will manufacture and distribute.

“With the support of GB Pharma Holdings, Immune Therapeutics Incorporation and American Hospitals & Resorts (AHAR), Fidson will gain from this partnership exclusive distribution rights to the internationally recognized immune therapy LodonalTM (Low Dose Naltrexone). It is expected that such collaboration will bring global recognition to Fidson’s pharmaceutical enterprise.

“As Fidson’s Managing Director and Chief Executive Officer. Dr. Fidelis Akhagboso Ayebae has turned his company into a leading Nigerian pharmaceutical company, which is publicly traded with annual US earnings of $60.5 million, making it one of the largest such pharmaceutical companies in Nigeria.”

Ayebae said: “My goal is to provide Nigerians with excellent quality pharmaceuticals at affordable prices. I am very confident that working with USP will help me achieve this end.”

To prepare for major growth, Ayebae has invested $55 million into building a six-line pharmaceutical manufacturing plant in Ogun State, Nigeria. The new plant is expected to more than double production and expand Fidson’s outreach into Nigeria and Africa.

President and Chief Executive Officer (CEO) of GB Pharma Holdings of Washington, DC, Dr. Gloria B. Herndon, said he r company will assist in this growth. Positioned to provide affordable and sustainable healthcare solutions throughout Africa, she will be a behind-the-scenes catalyst that will offer specialized expertise and outreach for helping Fidson develop its pharmaceutical market.